Robert L. Shepard

2.5k total citations
34 papers, 2.0k citations indexed

About

Robert L. Shepard is a scholar working on Oncology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Robert L. Shepard has authored 34 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Molecular Biology and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Robert L. Shepard's work include Drug Transport and Resistance Mechanisms (17 papers), Pharmacological Effects and Toxicity Studies (6 papers) and HIV/AIDS drug development and treatment (5 papers). Robert L. Shepard is often cited by papers focused on Drug Transport and Resistance Mechanisms (17 papers), Pharmacological Effects and Toxicity Studies (6 papers) and HIV/AIDS drug development and treatment (5 papers). Robert L. Shepard collaborates with scholars based in United States, Canada and United Kingdom. Robert L. Shepard's co-authors include Anne H. Dantzig, James J. Starling, Jin Cao, Susan E. Pratt, Steven Wrighton, Mark A. Winter, William L. Perry, William J. Ehlhardt, Todd M. Baughman and Linda B. Tabas and has published in prestigious journals such as Science, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Robert L. Shepard

32 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert L. Shepard United States	24	1.3k	831	440	318	218	34	2.0k
Rupeng Zhuo United States	5	1.2k 0.9×	846 1.0×	274 0.6×	306 1.0×	125 0.6×	6	1.7k
Markos Leggas United States	24	1.1k 0.8×	1.0k 1.2×	349 0.8×	140 0.4×	153 0.7×	79	2.5k
Yue Weng China	13	1.2k 0.9×	894 1.1×	273 0.6×	308 1.0×	124 0.6×	34	2.2k
Scott J. Weir United States	29	560 0.4×	928 1.1×	157 0.4×	163 0.5×	132 0.6×	106	2.2k
Kristen M. Pluchino United States	10	1.1k 0.9×	1.0k 1.3×	163 0.4×	207 0.7×	83 0.4×	14	2.0k
Mark A. Winter United States	13	694 0.5×	411 0.5×	192 0.4×	183 0.6×	148 0.7×	15	1.2k
Cindy Q. Xia United States	20	777 0.6×	481 0.6×	307 0.7×	106 0.3×	281 1.3×	47	1.4k
T Tsuruo Japan	11	2.4k 1.8×	1.1k 1.3×	962 2.2×	307 1.0×	410 1.9×	11	3.0k
Erasmus Schneider United States	20	938 0.7×	1.1k 1.3×	285 0.6×	163 0.5×	81 0.4×	42	1.8k
John M. Hilfinger United States	22	507 0.4×	641 0.8×	113 0.3×	297 0.9×	66 0.3×	44	1.5k

Countries citing papers authored by Robert L. Shepard

Since Specialization

Citations

This map shows the geographic impact of Robert L. Shepard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Shepard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Shepard more than expected).

Fields of papers citing papers by Robert L. Shepard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert L. Shepard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Shepard. The network helps show where Robert L. Shepard may publish in the future.

Co-authorship network of co-authors of Robert L. Shepard

This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. Shepard. A scholar is included among the top collaborators of Robert L. Shepard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert L. Shepard. Robert L. Shepard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tan, Bo, Sucai Dong, Robert L. Shepard, et al.. (2015). Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells. Journal of Biological Chemistry. 290(25). 15812–15824. 38 indexed citations

Pratt, Susan E., Robert L. Shepard, Gregory P. Donoho, et al.. (2013). Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts. Molecular Cancer Therapeutics. 12(4). 481–490. 24 indexed citations

Pratt, Susan E., et al.. (2013). Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells. Clinical Cancer Research. 19(5). 1159–1168. 90 indexed citations

Tan, Bo, Debra A. Young, Tao Wang, et al.. (2012). Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, in Human Cancer Cells. Journal of Biological Chemistry. 288(5). 3500–3511. 135 indexed citations

Pratt, Susan E., et al.. (2011). Abstract 2981: Carboxylesterase 2 hydrolyzes a gemcitabine prodrug (LY2334737) and provides a patient tailoring biomarker. Cancer Research. 71(8_Supplement). 2981–2981. 2 indexed citations

Holzer, Timothy R., Kathleen M. Heinz-Taheny, Darryl Ballard, et al.. (2010). Abstract B31: Potential for patient tailoring for prodrug of gemcitabine (LY2334737) by assessment carboxylesterase II expression in solid tumor biopsies. Clinical Cancer Research. 16(14_Supplement). B31–B31. 2 indexed citations

Pratt, Susan E., Robert L. Shepard, Ramani A. Kandasamy, et al.. (2005). The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Molecular Cancer Therapeutics. 4(5). 855–863. 186 indexed citations

Sampath, Janardhan, Robert L. Shepard, Xiaoling Xia, et al.. (2003). Human SPF45, a Splicing Factor, Has Limited Expression in Normal Tissues, Is Overexpressed in Many Tumors, and Can Confer a Multidrug-Resistant Phenotype to Cells. American Journal Of Pathology. 163(5). 1781–1790. 63 indexed citations

Dantzig, Anne H., Robert L. Shepard, Susan E. Pratt, et al.. (2003). Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP-binding cassette (ABC) drug transporters. Biochemical Pharmacology. 67(6). 1111–1121. 31 indexed citations

10.

Mao, Qingcheng, Wei Qiao Qiu, Peter A. Lander, et al.. (2002). GSH-dependent Photolabeling of Multidrug Resistance Protein MRP1 (ABCC1) by [125I]LY475776. Journal of Biological Chemistry. 277(32). 28690–28699. 50 indexed citations

11.

Shepard, Robert L., Jin Cao, James J. Starling, & Anne H. Dantzig. (2002). Modulation of P‐glycoprotein but not MRP1‐ or BCRP‐mediated drug resistance by LY335979. International Journal of Cancer. 103(1). 121–125. 113 indexed citations

12.

Ekins, Sean, Richard B. Kim, Brenda F. Leake, et al.. (2002). Three-Dimensional Quantitative Structure-Activity Relationships of Inhibitors of P-Glycoprotein. Molecular Pharmacology. 61(5). 964–973. 138 indexed citations

13.

Qian, Yueming, Caroline E. Grant, Christopher J. Westlake, et al.. (2002). Photolabeling of Human and Murine Multidrug Resistance Protein 1 with the High Affinity Inhibitor [125I]LY475776 and Azidophenacyl-[35S]Glutathione. Journal of Biological Chemistry. 277(38). 35225–35231. 39 indexed citations

14.

Ekins, Sean, Richard B. Kim, Brenda F. Leake, et al.. (2002). Application of Three-Dimensional Quantitative Structure-Activity Relationships of P-Glycoprotein Inhibitors and Substrates. Molecular Pharmacology. 61(5). 974–981. 30 indexed citations

15.

Dantzig, Anne H., et al.. (2000). Cytotoxic Responses to Aromatic Ring and Configurational Variations in α-Conidendrin, Podophyllotoxin, and Sikkimotoxin Derivatives. Journal of Medicinal Chemistry. 44(2). 180–185. 13 indexed citations

16.

Norman, Bryan H., Anne H. Dantzig, Julian S. Kroin, et al.. (1999). Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146. Bioorganic & Medicinal Chemistry Letters. 9(23). 3381–3386. 23 indexed citations

17.

Laska, Dennis A., et al.. (1999). Evaluation of an in vitro coculture model for the blood-brain barrier: Comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources. In Vitro Cellular & Developmental Biology - Animal. 35(10). 580–592. 24 indexed citations

18.

Shepard, Robert L., et al.. (1998). Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochemical Pharmacology. 56(6). 719–727. 49 indexed citations

19.

Starling, James J., Robert L. Shepard, Jin Cao, et al.. (1997). Pharmacological characterization of LY335979: A potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Advances in Enzyme Regulation. 37. 335–347. 70 indexed citations

20.

Hazlett, Robert N., et al.. (1973). Analysis of normal paraffin oxidation products in the presence of hydroperoxides. Analytical Chemistry. 45(14). 2388–2392. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact